Zimmer Biomet (NYSE:ZBH) exceeds Q3 2026 expectations

Zimmer Biomet reported Q3 revenue of $2bn, up 3.1% YoY, and raised its 2026 outlook. Earnings per share are now expected to be $8.50-$8.60, with revenue growth forecasted at 4.4%-4.9%. Shares rose 9.1% to $105.90 at market open. The company's CEO attributed the growth to its diversification strategy and innovation.

Zimmer Biomet (ZBH) reported Q3 net earnings of $191.6M ($1.0 per share), down from $230.9M ($1.16 per share) a year earlier. Adjusted earnings were $362.8M ($1.90 per share), with net sales rising 3.1% to $2.06B. The company raised its FY26 adjusted EPS outlook to $8.50-$8.60 and revenue growth forecast to 4.4%-4.9%.

Zimmer Biomet (ZBH) reported Q3 EPS of $1.90, beating estimates by $0.02, with revenue at $2.06B, exceeding expectations. The company expects FY 2026 EPS of $8.50-$8.60, below the consensus of $8.54. ZBH stock is up 10.86% over 12 months.

Zimmer Biomet (ZBH) reported Q3 adjusted EPS of $1.90, beating estimates by $0.02, with revenue of $2.06B, up 3.1% YoY. The company raised its 2026 adjusted EPS guidance to $8.50-$8.60. Shares rose 1.5% post-results. Key segments like Hips and Technology & Data showed strong growth, while Knees declined.

Zimmer Biomet Holdings Inc. (ZBH) reported Q3 profit of $191.6M, or $1 per share, beating estimates. Adjusted EPS was $1.90, and revenue was $2.06B, also exceeding forecasts. The company expects full-year EPS of $8.50-$8.60. (Zacks)

Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, up 3.1% YoY. EPS was $1.00, adjusted EPS was $1.90. The company raised its 2026 guidance, expecting 3.0%–3.5% revenue growth and adjusted EPS of $8.50–$8.60. Strong performance in Hips, S.E.T., and Technology & Data, Bone Cement and Surgical franchises. Extended agreement with THINK Surgical and opened a new training facility.